Litigation

Recent Posts

Russell Budd Announces Opening Of Baron & Budd P.C. Office In Miami
Posted on 10 Aug 2010 by LexisNexis Litigation Resource Community Staff

MIAMI - Russell Budd has announced the opening of plaintiff's law firm Baron & Budd, P.C. 's new office in Miami. The new office will offer its services to individuals and businesses with environmental issues as well as those victimized... Read More

$2M N.J. Accutane Verdict Reversed, 2 Defense Verdicts Affirmed On Appeal
Posted on 4 Aug 2014 by Tom Moylan

TRENTON, N.J. — (Mealey’s) A New Jersey appeals panel on Aug. 4 vacated a $2,125,617 Accutane bowel injury verdict and affirmed defense verdicts in two other cases tried at the same time ( Gillian Gaghan v. Hoffman-La Roche Inc., et al. ,... Read More

Pennsylvania Appeals Court Affirms $10M Children’s Motrin TEN Injury Verdict
Posted on 23 Jul 2014 by Tom Moylan

PHILADELPHIA — (Mealey’s) A Pennsylvania appeals court panel on July 22 affirmed a $10 million Children’s Motrin verdict for a girl who suffered toxic epidermal necrolysis (TEN) after being given the over-the-counter pain/fever reducer... Read More

$2.36B Glaxo Charge Covers Avandia, Paxil Litigation, Other Legal Costs
Posted on 15 Jul 2010 by Tom Moylan

LONDON - (Mealey's) GlaxoSmithKline PLC (GSK) on July 15 said it expects to take a $2.36 billion charge against earnings to settle several legal issues, including settling "the substantial majority" of Avandia product liability cases and... Read More

Norton Rose Fulbright: FDA’s Expanded Oversight Of ‘High-risk’ Diagnostic Devices
Posted on 7 Aug 2014 by Norton Rose Fulbright

By Cori Annapolen Goldberg and Lidia Niecko-Najjum In efforts to ensure that in vitro diagnostic devices 1 provide accurate, consistent and reliable results, the US Food and Drug Administration ("FDA" or "the Agency") 1) issued... Read More

McNeil Pleads Guilty, Pays $25M For Making Adulterated Children’s Medicines
Posted on 11 Mar 2015 by Tom Moylan

PHILADELPHIA — (Mealey’s) The McNeil-PPC Inc. subsidiary of Johnson & Johnson on March 10 pleaded guilty to a federal misdemeanor criminal charge of making adulterated children’s over-the-counter medicines and agreed to pay a criminal... Read More

Defense Verdict Returned In Purported 1st Zoloft Birth Defect Trial
Posted on 20 Apr 2015 by Tom Moylan

ST. LOUIS — (Mealey’s) A Missouri state court jury on April 17 returned a defense verdict in a Zoloft birth defect trial said by the parties to be the first trial of its kind in the nation ( Kristyn Pesante, et al. v. Pfizer, Inc. , No. 122... Read More

U.S. High Court Denies Review Of Last Pending Appeal Of Generic Label-Update Claim
Posted on 18 May 2015 by Tom Moylan

WASHINGTON, D.C. — (Mealey’s) The U.S. Supreme Court on May 18 denied review in the last pending “failure-to-update-warnings” preemption appeal by generic drug manufacturers ( Teva Pharmaceuticals USA, Inc., et al. v. Paul E. Hassett... Read More

6th Circuit Reverses Preemption-Based Dismissal Of Diet Drug Negligence Claims
Posted on 18 Aug 2010 by Michael Lefkowitz

CINCINNATI - (Mealey's) Citing the Supreme Court's rejection of implied preemption of pharmaceutical product liability in Wyeth v. Diana Levine (No. 06-1249, U.S. Sup.; 2009 U.S. LEXIS 1774), the Sixth Circuit U.S. Court of Appeals on Aug. 18... Read More

Another Specialty Pharmacy Settles Exjade False Claims Allegations For $45 Million
Posted on 1 May 2015 by Tom Moylan

NEW YORK —(Mealey’s) Specialty pharmacy Accredo Health Group Inc. on April 30 agreed to pay $45 million to settle a whistle-blower’s allegations that its efforts to push prescriptions for the iron chelation drug Exjade resulted in false... Read More

Alabama High Court Again Says Brand-Name Drug Makers Liable In Generic Injury Case
Posted on 18 Aug 2014 by Tom Moylan

MONTGOMERY, Ala. —(Mealey’s) A brand-name drug manufacturer may be liable under Alabama law for fraud or misrepresentation in a drug label used by generic drug makers, the Alabama Supreme Court held Aug. 15 after reconsidering its 2013 decision... Read More

N.J. Risperdal Jury Finds Diabetes Warning Lacking, But Drug Didn't Cause Disease
Posted on 17 Feb 2012 by Tom Moylan

NEW BRUNSWICK, N.J. - (Mealey's) A Risperdal personal injury trial ended Feb. 16 in a defense verdict for Johnson & Johnson subsidiary Janssen Pharmaceuticals Inc. after a New Jersey state court jury found that Janssen failed to warn about the... Read More

N.H. Jury Awards $21 Million To Woman Claiming Pain Medication Caused Blindness
Posted on 9 Sep 2010 by Tom Moylan

CONCORD, N.H. - (Mealey's) A federal jury in New Hampshire on Sept. 8 awarded $21 million to a woman who claims that her use of a generic version of the nonsteroidal anti-inflammatory drug Clinoril caused her to suffer Stevens-Johnson syndrome (SJS... Read More

Pa. High Court: Drug Company Lacks Standing To Challenge State’s Outside Counsel
Posted on 18 Aug 2010 by Tom Moylan

PHILADELPHIA - (Mealey's) Janssen Pharmaceutica Inc. lacks standing under Pennsylvania law to challenge the hiring of outside counsel to represent the state in a Risperdal off-label marketing lawsuit, the Pennsylvania Supreme Court ruled Aug. 17 ... Read More

AstraZeneca Settles Nearly 4,000 Seroquel Injury Claims; Terms Confidential
Posted on 30 Jul 2010 by Tom Moylan

LONDON - (Mealey's) AstraZeneca PLC said July 29 that it has agreed in principle to settle with nearly 4,000 Seroquel product liability plaintiffs. The company said settlement terms are confidential. In notes to its second-quarter financial... Read More